Lilly's gain is Novo Nordisk's loss: more diabetes data from EASD 2018

5 October 2018

Germany’s Boehringer Ingelheim and the USA’s Eli Lilly (NYSE: LLY) have presented positive long-term results from the CARMELINA trial of Tradjenta (linagliptin) at the annual meeting of the European Association for the Study of Diabetes (EASD), in Berlin.

Shares in the New Jersey-based firm, which also presented impressive weight loss data for its diabetes candidate LY3298176, finished the day up over 4% in New York on Thursday.

Rival diabetes firm Novo Nordisk (NOV: N) saw a concurrent 6% slump in its share price.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK